IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS. Monday, June 2, 2025 Cancer News. Advertisement PR Newswire THOUSAND OAKS, Calif., June 2, 2025 ...

IMDELLTRA™ (tarlatamab-dlle) Important Safety Information. WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif., April 11, 2025 ...

The Food and Drug Administration (FDA) approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung cancer (SCLC) that progressed on or after a platinum-based ...

Imdelltra is already approved by the Food and Drug Administration (FDA) for the treatment of patients with extensive stage small cell lung cancer (ES-SCLC) ...

Amgen’s Imdelltra, a delta-like ligand 3 targeting Bispecific T-cell Engager (BiTE) therapy, was approved by the FDA in 2024 for pre-treated extensive-stage small cell lung cancer ...

Amgen has announced the US Food and Drug Administration's (FDA) accelerated approval for its IMDELLTRA (tarlatamab-dlle) to treat adults with extensive-stage small cell lung cancer (ES-SCLC). A ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif., April 11, 2025 ...

IMDELLTRA ® (tarlatamab-dlle) Important Safety Information (USPI) WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME ...

IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen researchers to bind to both DLL3 on tumor cells and CD3 on T cells, thereby activating T cells to kill DLL3-expressing SCLC ...

THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN ) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA ® (tarlatamab-dlle ...